Swiss start-up adapts human health research for animal uses

08.05.2015 13:18

Gour Medical, founded in 2014, is a Swiss based veterinary biomedical company leveraging the advances in human research and applying them to medical solutions for companion animals. Gour has recently in-licensed a compound from Actelion and has started a research partnership with the French National Center for Scientific Research (CNRS).

Gour was founded by an experienced team of scientists, operating at the junction between human and veterinary health and medicine, who came up with a simple idea: finding the best of human health and medical science research and make the drugs, knowledge and leading technologies available to our animal companions.

Recently, Gour Medical SA has entered into a definitive worldwide license agreement with Actelion Pharmaceuticals Ltd for the veterinary development of one of Actelion’s early-stage clinical dual orexin receptor antagonists, which the company had decided not to pursue further.

Gour plans to develop the compound and eventually bring to the market a new treatment to reduce anxiety, hypervigilance and restlessness in dogs during stress situations related to transport, loud noises and separation, a very large and still highly unmet medical need.

Gour plans to conduct a proof-of-concept study to establish the efficacy of the compound in reducing anxiety, hypervigilance and restlessness in dogs during transport.

In addition Gour signed a first research partnership with French National Center for Scientific Research CNRS for the development of recombinant monoclonal antibody for therapeutic use on dogs and cats.

Gour plans to develop a therapeutic recombinant chimeric monoclonal antibody and to launch it in the market. A first product is under development for the treatment of Atopic Dermatitis for dogs, a substantial and still unmet medical need. As a first step, Gour plans to conduct a proof-of-concept study to establish the efficacy of the recombinant chimeric antibody in this indication.

Please login or
register to comment

Please login or sign up to comment. Commenting guidelines

Please login or
register to use the
bookmark feature

Related News

Principal

20.07.2018
Editorial

Support at home and away

Partners

Contributors

By continuing to use this website you agree with our TERMS AND CONDITIONS

In order to provide the best quality for you, our system uses "cookies", which are stored on your device. Cookies are necessary to identify what information (job advertisement, questionnaire, etc) you have already seen. IP address is used for the same purposes as described above.

When creating a profile, applying to the newsletter, job subscriptions and etc, you agree that the data, which you have entered, will be stored and processed in the system in order to provide services, which you have applied for.

We do NOT sell your personal data to any 3rd party services.

You must be 18 or older years old to use our services. If you are underage, you must have a permission to use our services from your parent or guardian. It is necessary in order to store and process your data.

By continuing to use our services, you agree with the these terms. You can withdraw your agreement at any time, by deleting cookies from your device and by sending request for deleting your data to the administrator.